Revenue
2022
2023
2024
2025
Allergy Therapeutics plc (AGY)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £55.0M | £55.2M | £59.6M | £72.8M |
| Research & development | £15.4M | £22.9M | £20.1M | £15.7M |
| Operating expenses | £57.5M | £63.8M | £68.1M | £61.8M |
| Operating income | −£28.2M | −£34.0M | −£34.9M | −£12.2M |
| Operating margin | −51.16% | −61.63% | −58.58% | −16.83% |
| EBITDA | −£28.3M | −£30.7M | −£35.1M | −£7.8M |
| EBITDA margin | −51.48% | −55.69% | −58.91% | −10.75% |
| Net income | −£40.1M | −£38.6M | −£43.1M | −£13.8M |
| Net profit margin | −72.91% | −69.97% | −72.28% | −18.93% |
| Basic EPSper basic share | -£0.01 | -£0.01 | -£0.08 | -£0.02 |
| Diluted EPSper diluted share | -£0.01 | -£0.01 | -£0.08 | -£0.02 |